Non-promotional infographic

Patient support

Resources and downloadable booklets created to help you support your patients who have been prescribed Zejula (niraparib).

Patient resources

For your patients already on Zejula, we offer a Patient Support Programme and/or Homecare Medicines Service

GSK and HealthNet offer a 3-part service to help you monitor your patients throughout their treatment.

Image of blood monitoring
Image of blood pressure measurement
Image of medicine with Zejula delivery wording
Image of blood monitoring
Image of blood pressure measurement
Image of medicine with Zejula delivery wording

Want to discover more about how we can support you and your patients?

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

MoA, mechanism of action; QoL, quality of life.

References

  1. ZEJULA Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

June 2023 | PM-GB-NRP-WCNT-220010 (V2.0)